Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...

We regret to report that long term Biogen Inc. (NASDAQ:BIIB) shareholders have had that experience, with the share price dropping 20% in three years, versus a market return of about 89%.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the September 2025 expiration. One of the key data points that goes into the price an option buyer is willing to ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

At $310.58, the average BIIB stock price target of $310.58 suggests a modest upside potential of 1.8% from current levels. Biogen stock has rallied over 27% so far this year. IQVIA Holdings (IQV ...

Biogen (NASDAQ:BIIB) has had a great run on the share market with its stock up by a significant 30% over the last three months. Given the company's impressive performance, we decided to study its ...

Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session. This move lagged the S&P 500's daily loss of 0.74%. Elsewhere, the Dow lost 0.9% ...

Another notable valuation metric for BIIB is its P/B ratio of 3.26. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities.

In the latest market close, Biogen Inc. (BIIB) reached $247.52, with a +1.1% movement compared to the previous day. This change outpaced the S&P 500's 0.76% gain on the day. Elsewhere, the Dow ...